Liom, a Swiss HealthTech company based in Schwyz, has secured an additional €13.9 million (CHF 13 million) as an extension to its Series A funding round.
The investment brings the company’s total Series A financing to €40.8 million (CHF 38 million) and total capital raised to date to €67.6 million (CHF 63 million).
The extension was led by existing investors and joined by new backers including Red Bull Ventures, former On Running co-CEO Marc Maurer, former Yemeksepeti co-founder and CTO Melih Odemis, and Alejo Costa Ribalta, partner at CRB Health Tech and former Philips and GE Healthcare executive.
Progress toward wearable-ready glucose monitoring
Liom is developing a non-invasive glucose-monitoring wearable designed to provide continuous metabolic insights without needles or calibration. According to founder and CEO Leo Grünstein, the latest funding validates both the scientific approach and the company’s ability to translate breakthrough research into a wearable-friendly form factor.
The company recently achieved a major technical milestone by miniaturising its proprietary Raman spectroscopy platform. This breakthrough enables significantly higher light throughput compared to existing solutions, delivering performance that exceeds lab-scale devices while supporting smartwatch-sized hardware, more than 24 hours of battery life, and scalable manufacturing.
Advertisement
Positioning within Europe’s growing preventive health market
Liom’s funding comes amid strong investor interest in European HealthTech startups focused on wearables, biosensing, and preventive care. Across 2025, startups building continuous monitoring and biomarker-based platforms have attracted substantial capital, reflecting confidence in technologies that extend health insights beyond traditional clinical environments.
Together, these investments highlight a broader shift toward personalised, always-on health data, with Liom’s approach targeting one of the most sought-after capabilities in consumer and medical wearables: accurate, needle-free glucose tracking.
From research to commercialisation
Founded in 2017, Liom Health, formerly known as Spiden, focuses on preventive and personalised health monitoring through real-time biophysical feedback. The company’s first product, expected in 2028, aims to offer a comprehensive view of metabolic health via non-invasive glucose measurement.
Liom has demonstrated calibration-free glucose monitoring across more than 130 subjects, positioning its platform as a unique solution in the field. The addition of Marc Maurer as both investor and board member supports Liom’s transition from research and development toward product strategy, branding, and commercial scale.
Maurer noted that easy access to glucose data through a wrist-worn device could help consumers and athletes better understand how nutrition and movement affect their bodies, potentially expanding the wearable market beyond current sensor capabilities.
Next steps
With the expanded Series A in place, Liom plans to continue refining its wearable platform, preparing for large-scale manufacturing, and advancing toward regulatory and commercial milestones. The company aims to play a central role in the next generation of health wearables by making continuous metabolic monitoring accessible, practical, and consumer-ready.
